15 January 2021 - Late treatment study
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
, The Lancet, doi:10.1016/S0140-6736(21)00897-7 (press release 1/15/2021) (Peer Reviewed)
RCT 16,287 hospitalized patients in the UK, showing no significant differences with convalescent plasma treatment. Subgroup analysis shows better results for those treated <= 7 days from symptom onset. NCT04381936.
|
risk of death, no change, RR 1.00, p = 0.95, treatment 1,399 of 5,795 (24.1%), control 1,408 of 5,763 (24.4%), NNT 345, day 28.
|
|
risk of no hospital discharge, 1.0% higher, RR 1.01, p = 0.57, treatment 1,963 of 5,795 (33.9%), control 1,941 of 5,763 (33.7%), day 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Recovery Collaborative Group et al., 1/15/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 1 author.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.